Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies-Reference-Cited by-同舟云学术

Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies

Published:2021-01-15 Issue:8 Volume:27 Page:2190-2199
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Ansell Stephen M.^ORCID,Maris Michael B.,Lesokhin Alexander M.,Chen Robert W.,Flinn Ian W.^ORCID,Sawas Ahmed,Minden Mark D.,Villa Diego^ORCID,Percival Mary-Elizabeth M.,Advani Anjali S.,Foran James M.,Horwitz Steven M.,Mei Matthew G.^ORCID,Zain Jasmine,Savage Kerry J.,Querfeld Christiane,Akilov Oleg E.^ORCID,Johnson Lisa D.S.^ORCID,Catalano Tina,Petrova Penka S.,Uger Robert A.,Sievers Eric L.^ORCID,Milea Anca,Roberge Kathleen,Shou Yaping,O'Connor Owen A.

Funder

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Therapy-induced Dermatotoxicity as a Window to Understanding Skin Immunity;Hematology/Oncology Clinics of North America;2024-10

2. In situ reprogramming of tumor-associated macrophages enhances cancer immunotherapy;Nano Today;2024-10

3. Modulating macrophage-mediated programmed cell removal: An attractive strategy for cancer therapy;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2024-09

4. Single-cell RNA sequencing and cell–cell communication analysis reveal tumor microenvironment associated with chemotherapy responsiveness in ovarian cancer;Clinical and Translational Oncology;2024-08-09

5. Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia;Blood;2024-08-08